Seres Therapeutics price to sales ratio MCRB

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: 11.0×
10-year median: 10.8×
Against its 10-year history: 50th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.7× to 145×
Peer median: 0.9×

Seres Therapeutics' price to sales ratio is 11.0× as of Oct 23, 2026.

That is above its ten-year median of 10.8×, close to the middle of its last ten years.

Over that time it ranged from 0.7× in Apr 2024 to 145× in Jun 2023.

The median for 3 large drugmakers of a similar size is 0.9×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	11.0×	11.0×	30.2×
2025	n/m a value too high to mean anything
2024	1.1×	0.7×	1.6×
2023	1.4×	1.0×	145×
2022	52.2×	1.9×	75.8×
2021	4.9×	4.6×	108×
2020	96.1×	5.4×	135×
2019	7.5×	3.0×	12.6×
2018	9.4×	7.3×	16.6×
2017	12.8×	11.9×	30.7×
2016	21.3×	21.0×	160×

Against its peers

Companies in Drug Manufacturers - General nearest Seres Therapeutics' size, closest first, today.

Company	Price to sales ratio
MCRBSeres Therapeutics	11.0×
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
Peer median	0.9×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Seres Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.